Assessment of switching from salmeterol/fluticasone to indacaterol/glycopyrronium in a symptomatic COPD patient cohort (FLASH)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2015
This study will investigate whether switching symptomatic COPD patients from a fixed-dose combination of salmeterol/fluticasone 50/500 µg b.i.d. to a fixed dose combination of QVA149 110/50 µg o.d. leads to improved lung function and airflow. It will also assess the effect on symptom burden, breathlessness, and use of rescue medication after this switch.
Epistemonikos ID: 764f7e7abd21cbb0b76bd13d8234e9a53e9220b6
First added on: May 12, 2024